FREE SHIPPING over $40
OVER 9000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Home / Equine Research Bank / Cytotechnology / Expression of scleraxis and tenascin C in equine adipose and...
Cytotechnology2013; 66(1); 27-35; doi: 10.1007/s10616-012-9533-3

Expression of scleraxis and tenascin C in equine adipose and umbilical cord blood derived stem cells is dependent upon substrata and FGF supplementation.

Abstract: Recovery from tendon injury is based on long periods of rest, which results in sub-optimal repair, often replacing tendon with fibrocartilage scar tissue. Recently, the use of stem cells in equine tendon repair has been attempted with variable success. The objective of this work was to determine the expression of scleraxis (scx) and tenascin C (TnC), two markers of tenocytes, in adipose (AdMSC) and umbilical cord blood (UCB) stem cells during culture on various substrata and in response to fibroblast growth factor (FGF) treatment. Equine UCB and AdMSC were cultured on gelatin-coated plasticware, 30 % matrigel or collagen-coated Cytodex beads and treated with 10 ng/ml FGF2, FGF4 or FGF5 prior to measurement of proliferation, kinase activity and tenocyte gene expression. Supplementation with FGF2 or FGF5 activated the ERK1/2 signaling pathway in AdMSC and UCB; no effect of FGF4 was observed in UCB. FGF2 increased proliferation in AdMSC but not UCB. Conversely, FGF5 stimulated proliferation of UCB. Culture in matrigel increased scx expression in both cell populations and increased TnC in AdMSC. In AdMSC grown in matrigel, supplementation with FGF2 or FGF5 increased TnC expression. Thus, culture conditions (substrata and FGF supplementation) impact markers of tenocytes in AdMSC and UCB stem cells, indicating that careful consideration should be given to culture conditions prior to use of UCB or AdMSC as therapeutic aids. Optimal culture conditions may promote early differentiation of these cells, improving their ability to aid tendon regeneration and facilitating more efficient recovery from tendon injury.
Get Full Text
Publication Date: 2013-01-09 PubMed ID: 23299298PubMed Central: PMC3886543DOI: 10.1007/s10616-012-9533-3Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Journal Article

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

This research examines how the growth conditions, particularly growth surface (substrata) and growth factor supplementation, affect the expression of key markers in stem cells derived from horse fat and umbilium cord blood, aiming to improve the cells’ ability to assist in tendon repair.

Underlying Research

  • Recovery from tendon injuries traditionally requires long rest periods and often involves creation of fibrocartilage scar tissue instead of a perfect tendon repair.
  • Stem cell therapy has recently been attempted to rectify tendon injuries in horses, providing a potential avenue for more effective and efficient repair. However, the results have been inconsistent.
  • This study aimed to improve our understanding of stem cell behavior, and specifically how tendon-related marker (scleraxis and tenascin C) expression is impacted by the culture conditions.

Experimental Approach

  • The researchers isolated stem cells from horse fat (adipose or AdMSC) and umbilical cord blood (UCB).
  • The cells were grown on different surfaces (gelatin-coated plastic, matrigel, collagen-coated beads) and with different fibroblast growth factors (FGF2, FGF4, and FGF5).
  • Following this, the researchers measured cell proliferation, enzyme activity, and expression of tendon-related markers.

Key Findings

  • FGF2 and FGF5 supplementation activated a signaling pathway (ERK1/2) in both fat- and cord blood-derived stem cells. FGF4, however, had no effect in the umbilical cord blood-derived stem cells.
  • FGF2 increased cell growth (proliferation) in fat-derived stem cells, but not in cord blood-derived cells. On the other hand, FGF5 enhanced proliferation of cord blood-derived stem cells.
  • Both types of stem cells increased scleraxis expression when grown on matrigel. In addition, adipose derived cells grown on matrigel increased their tenascin C expression.
  • FGF2 or FGF5 addition further increased the expression of tenascin C in fat-derived stem cells grown on matrigel.

Implications and Conclusions

  • The findings underline the importance of carefully selecting the culture conditions to promote more successful therapeutic outcomes when utilizing stem cells derived from adipose or umbilical cord blood for tendon repair.
  • Optimal culture conditions might enhancing early cell differentiation, consequently improving their ability to contribute to tendon regeneration and facilitate more effective recovery from tendon injury.

Cite This Article

APA
Reed SA, Johnson SE. (2013). Expression of scleraxis and tenascin C in equine adipose and umbilical cord blood derived stem cells is dependent upon substrata and FGF supplementation. Cytotechnology, 66(1), 27-35. https://doi.org/10.1007/s10616-012-9533-3

Publication

Cytotechnology
ISSN: 0920-9069
NlmUniqueID: 8807027
Country: United States
Language: English
Volume: 66
Issue: 1
Pages: 27-35

Researcher Affiliations

Reed, Sarah A
  • Department of Animal Sciences, University of Florida, Gainesville, FL, 32611, USA, sarah.reed@uconn.edu.
Johnson, Sally E

    References

    This article includes 35 references
    1. Brent AE, Tabin CJ. FGF acts directly on the somitic tendon progenitors through the Ets transcription factors Pea3 and Erm to regulate scleraxis expression.. Development 2004;131:3885–3896.
      doi: 10.1242/dev.01275pubmed: 15253939google scholar: lookup
    2. Brent AE, Schweitzer R, Tabin CJ. A somitic compartment of tendon progenitors.. Cell 2003;113:235–248.
      doi: 10.1016/S0092-8674(03)00268-Xpubmed: 12705871google scholar: lookup
    3. Castellani LW, Gargalovic P, Febbraio M, Charugundla S, Jien ML, Lusis AJ. Mechanisms mediating insulin resistance in transgenic mice overexpressing mouse apolipoprotein A-II.. J Lipid Res 2004;45:2377–2387.
      doi: 10.1194/jlr.M400345-JLR200pubmed: 15466364google scholar: lookup
    4. Chung AE, Durkin ME. Entactin: structure and function.. Am J Respir Cell Mol Biol 1990;3:275–282.
      doi: 10.1165/ajrcmb/3.4.275pubmed: 2119632google scholar: lookup
    5. Clase KL, Mitchell PJ, Ward PJ, Dorman CM, Johnson SE, Hannon K. FGF5 stimulates expansion of connective tissue fibroblasts and inhibits skeletal muscle development in the limb.. Dev Dyn 2000;219:368–380.
      doi: 10.1002/1097-0177(2000)9999:9999<::AID-DVDY1056>3.0.CO;2-8pubmed: 11066093google scholar: lookup
    6. Clegg PD, Strassburg S, Smith RK. Cell phenotypic variation in normal and damaged tendons.. Int J Exp Pathol 2007;88:227–235.
      doi: 10.1111/j.1365-2613.2007.00549.xpmc: PMC2517321pubmed: 17696903google scholar: lookup
    7. Clements DA, Wang JK, Dionne CA, Goldfarb M. Activation of fibroblast growth factor (FGF) receptors by recombinant human FGF-5.. Oncogene 1993;8:1311–1316.
      pubmed: 8386828
    8. Crovace A, Lacitignola L, De Siena R, Rossi G, Francioso E. Cell therapy for tendon repair in horses: an experimental study.. Vet Res Commun 2007;31:281–283.
      doi: 10.1007/s11259-007-0047-ypubmed: 17682895google scholar: lookup
    9. Cserjesi P, Brown D, Ligon KL, Lyons GE, Copeland NG, Gilbert DJ, Jenkins NA, Olson EN. Scleraxis: a basic helix-loop-helix protein that prefigures skeletal formation during mouse embryogenesis.. Development 1995;121:1099–1110.
      pubmed: 7743923
    10. Edom-Vovard F, Schuler B, Bonnin MA, Teillet MA, Duprez D. Fgf4 positively regulates scleraxis and tenascin expression in chick limb tendons.. Dev Biol 2002;247:351–366.
      doi: 10.1006/dbio.2002.0707pubmed: 12086472google scholar: lookup
    11. Espira L, Lamoureux L, Jones SC, Gerard RD, Dixon IM, Czubryt MP. The basic helix-loop-helix transcription factor scleraxis regulates fibroblast collagen synthesis.. J Mol Cell Cardiol 2009;47:188–195.
      doi: 10.1016/j.yjmcc.2009.03.024pubmed: 19362560google scholar: lookup
    12. Eswarakumar VP, Lax I, Schlessinger J. Cellular signaling by fibroblast growth factor receptors.. Cytokine Growth Factor Rev 2005;16:139–149.
      doi: 10.1016/j.cytogfr.2005.01.001pubmed: 15863030google scholar: lookup
    13. Hayashi Y, Furue MK, Okamoto T, Ohnuma K, Myoishi Y, Fukuhara Y, Abe T, Sato JD, Hata R, Asashima M. Integrins regulate mouse embryonic stem cell self-renewal.. Stem Cells 2007;25:3005–3015.
      doi: 10.1634/stemcells.2007-0103pubmed: 17717067google scholar: lookup
    14. Kardon G. Muscle and tendon morphogenesis in the avian hind limb.. Development 1998;125:4019–4032.
      pubmed: 9735363
    15. Kuo CK, Tuan RS. Mechanoactive tenogenic differentiation of human mesenchymal stem cells.. Tissue Eng Part A 2008;14:1615–1627.
      doi: 10.1089/ten.tea.2006.0415pubmed: 18759661google scholar: lookup
    16. Lejard V, Brideau G, Blais F, Salingcarnboriboon R, Wagner G, Roehrl MH, Noda M, Duprez D, Houillier P, Rossert J. Scleraxis and NFATc regulate the expression of the pro-alpha1(I) collagen gene in tendon fibroblasts.. J Biol Chem 2007;282:17665–17675.
      doi: 10.1074/jbc.M610113200pubmed: 17430895google scholar: lookup
    17. Liu Y, Cserjesi P, Nifuji A, Olson EN, Noda M. Sclerotome-related helix-loop-helix type transcription factor (scleraxis) mRNA is expressed in osteoblasts and its level is enhanced by type-beta transforming growth factor.. J Endocrinol 1996;151:491–499.
      doi: 10.1677/joe.0.1510491pubmed: 8994394google scholar: lookup
    18. Longo UG, Ronga M, Maffulli N. Achilles tendinopathy.. Sports Med Arthrosc 2009;17:112–126.
      doi: 10.1097/JSA.0b013e3181a3d625pubmed: 19440139google scholar: lookup
    19. Mackie EJ, Ramsey S. Expression of tenascin in joint-associated tissues during development and postnatal growth.. J Anat 1996;188:157–165.
      pmc: PMC1167643pubmed: 8655402
    20. Muir T, Sadler-Riggleman I, Skinner MK. Role of the basic helix-loop-helix transcription factor, scleraxis, in the regulation of Sertoli cell function and differentiation.. Mol Endocrinol 2005;19:2164–2174.
      doi: 10.1210/me.2004-0473pubmed: 15831523google scholar: lookup
    21. Murchison ND, Price BA, Conner DA, Keene DR, Olson EN, Tabin CJ, Schweitzer R. Regulation of tendon differentiation by scleraxis distinguishes force-transmitting tendons from muscle-anchoring tendons.. Development 2007;134:2697–2708.
      doi: 10.1242/dev.001933pubmed: 17567668google scholar: lookup
    22. Nixon AJ, Dahlgren LA, Haupt JL, Yeager AE, Ward DL. Effect of adipose-derived nucleated cell fractions on tendon repair in horses with collagenase-induced tendinitis.. Am J Vet Res 2008;69:928–937.
      doi: 10.2460/ajvr.69.7.928pubmed: 18593247google scholar: lookup
    23. Pacini S, Spinabella S, Trombi L, Fazzi R, Galimberti S, Dini F, Carlucci F, Petrini M. Suspension of bone marrow-derived undifferentiated mesenchymal stromal cells for repair of superficial digital flexor tendon in race horses.. Tissue Eng 2007;13:2949–2955.
      doi: 10.1089/ten.2007.0108pubmed: 17919069google scholar: lookup
    24. Perez AV, Perrine M, Brainard N, Vogel KG. Scleraxis (Scx) directs lacZ expression in tendon of transgenic mice.. Mech Dev 2003;120:1153–1163.
      doi: 10.1016/j.mod.2003.08.003pubmed: 14568104google scholar: lookup
    25. Pryce BA, Brent AE, Murchison ND, Tabin CJ, Schweitzer R. Generation of transgenic tendon reporters, ScxGFP and ScxAP, using regulatory elements of the scleraxis gene.. Dev Dyn 2007;236:1677–1682.
      doi: 10.1002/dvdy.21179pubmed: 17497702google scholar: lookup
    26. Reed SA, Johnson SE. Equine umbilical cord blood contains a population of stem cells that express Oct4 and differentiate into mesodermal and endodermal cell types.. J Cell Physiol 2008;215:329–336.
      doi: 10.1002/jcp.21312pubmed: 17929245google scholar: lookup
    27. Reed SA, Johnson SE. Refinement of culture conditions for maintenance of undifferentiated equine umbilical cord blood stem cells.. J Equine Vet Sci 2012;32:360–366.
      doi: 10.1016/j.jevs.2011.12.004google scholar: lookup
    28. Schneider PR, Buhrmann C, Mobasheri A, Matis U, Shakibaei M. Three-dimensional high-density co-culture with primary tenocytes induces tenogenic differentiation in mesenchymal stem cells.. J Orthop Res 2011;29:1351–1360.
      doi: 10.1002/jor.21400pubmed: 21437969google scholar: lookup
    29. Schweitzer R, Chyung JH, Murtaugh LC, Brent AE, Rosen V, Olson EN, Lassar A, Tabin CJ. Analysis of the tendon cell fate using Scleraxis, a specific marker for tendons and ligaments.. Development 2001;128:3855–3866.
      pubmed: 11585810
    30. Smith TG, Sweetman D, Patterson M, Keyse SM, Munsterberg A. Feedback interactions between MKP3 and ERK MAP kinase control scleraxis expression and the specification of rib progenitors in the developing chick somite.. Development 2005;132:1305–1314.
      doi: 10.1242/dev.01699pubmed: 15716340google scholar: lookup
    31. Stojkovic M, Lako M, Strachan T, Murdoch A. Derivation, growth and applications of human embryonic stem cells.. Reproduction 2004;128:259–267.
      doi: 10.1530/rep.1.00243pubmed: 15333777google scholar: lookup
    32. Swasdison S, Mayne R. Location of the integrin complex and extracellular matrix molecules at the chicken myotendinous junction.. Cell Tissue Res 1989;257:537–543.
      doi: 10.1007/BF00221463pubmed: 2529032google scholar: lookup
    33. Taylor SE, Smith RK, Clegg PD. Mesenchymal stem cell therapy in equine musculoskeletal disease: scientific fact or clinical fiction?. Equine Vet J 2007;39:172–180.
      doi: 10.2746/042516407X180868pubmed: 17378447google scholar: lookup
    34. Taylor SE, Vaughan-Thomas A, Clements DN, Pinchbeck G, Macrory LC, Smith RK, Clegg PD. Gene expression markers of tendon fibroblasts in normal and diseased tissue compared to monolayer and three dimensional culture systems.. BMC Musculoskelet Disord 2009;10:27.
      doi: 10.1186/1471-2474-10-27pmc: PMC2651848pubmed: 19245707google scholar: lookup
    35. To WS, Midwood KS. Identification of novel and distinct binding sites within tenascin-C for soluble and fibrillar fibronectin.. J Biol Chem 2011;286:14881–14891.
      doi: 10.1074/jbc.M110.189019pmc: PMC3083171pubmed: 21324901google scholar: lookup
    Subscribe to our newsletter
    Join 99,357 horse owners like you who receive our email updates on horse health and nutrition.